AI Article Synopsis
- Social determinants of health (SDoH) significantly impact cancer outcomes, yet data collection on SDoH is largely absent from oncology clinical trials.
- A study involving a pediatric oncology trial found that a high percentage (87.5%) of participants agreed to take part in an SDoH investigation, with most completing baseline surveys and maintaining strong response rates over two years.
- The results demonstrate that incorporating SDoH data collection into oncology trials is both feasible and essential for improving health equity and understanding health disparities.
Article Abstract
Social determinants of health (SDoH) are associated with stark disparities in cancer outcomes, but systematic SDoH data collection is virtually absent from oncology clinical trials. Trial-based SDoH data are essential to ensure representation of marginalized populations, contextualize outcome disparities, and identify health-equity intervention opportunities. We report the feasibility of a pediatric oncology multicenter therapeutic trial-embedded SDoH investigation. Among 448 trial participants, 392 (87.5%) opted-in to the embedded SDoH study; 375 (95.7%) completed baseline surveys, with high longitudinal response rates (88.9-93.1%) over 24 months. Trial-embedded SDoH data collection is feasible and acceptable and must be consistently included within future oncology trials.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.29933 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!